Alzheimers Disease Neuroimaging Initiative 3 (ADNI3)
Brief description of study
Since its launch in 2004, the overarching aim of the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
has been realized
in informing the design
of therapeutic
trials in AD. ADNI3 continues the previously funded
ADNI1, ADNI-GO, and ADNI2
studies that have been combined
public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging,
genetic and biochemical biomarker characteristics of the entire
spectrum of Alzheimer’s disease (AD).
ADNI3 is the latest phase of the initiative. It is a non-treatment clinical research study to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in ongoing AD research.
Data from this research will help determine the best measures for diagnosis and disease monitoring , which will be used to accelerate the testing of therapeutic interventions and ultimately, improve Alzheimer's disease prevention and care.
Detailed description of study
Who can participate?
Individuals who are 55-90, who have a diagnosis of Mild Cognitive Impairment (MCI or Alzheimer's Disease (AD). Who have a reliable study partner who has frequent contact and who can accompanying you to the study visits for the duration on the study and who are willing to participate in repeated imaging and biomarker collection.
What does the study include?
If you agree and are eligible to participate in the study, you will be asked to come in for:
- an initial screening visit and baseline visit
- an annual or biannual follow-up clinic visit
Screening Procedures include:
- Brain imaging such as MRI and PET/CT scans
- Memory Testing
- Physical and Neurological Exam
- Lumbar Puncture
- Blood Draw
Before enrolling into the study, the participant and study partner must read, understand, and sign a formal consent, which fully explains the study.
Additional InformationParticipants will be compensated for their time and travel.Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
MCI,AD
-
Age: Between 55 Years - 90 Years
-
Gender: All
Updated on
31 Jul 2023.
Study ID: 825666
